Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu, China.
Department of Radiotherapy, West China Hospital, Sichuan University, Chengdu, China.
Future Oncol. 2022 Jun;18(20):2533-2543. doi: 10.2217/fon-2021-1523. Epub 2022 May 19.
To determine the antiemetic efficacy of a 6-day aprepitant schedule in patients receiving multiple-day cisplatin. Patients diagnosed with lung cancer and who were chemotherapy-naive were screened. The patients willing to use aprepitant were randomly divided into two groups: prolonged use of aprepitant (PA; 6-day aprepitant) and standard use of aprepitant (SA; 3-day aprepitant); the patients who rejected aprepitant were recruited into the control group (group C). Primary end points included the safety and the number of days without chemotherapy-induced nausea and vomiting. There was no statistical difference in adverse events among the three groups. The average days without chemotherapy-induced nausea and vomiting of group PA (18.28 ± 3.35) was significantly longer than in groups SA and C. Furthermore, better life function scores were achieved in group PA according to the Functional Living Index - Emesis questionnaire. In this study 6-day aprepitant was safe and more effective than standard 3-day aprepitant in controlling chemotherapy-induced nausea and vomiting due to 3-day cisplatin regimens.
为了确定接受多日顺铂治疗的患者使用为期 6 天的阿瑞匹坦方案的止吐疗效。筛选出被诊断患有肺癌且未经化疗的患者。愿意使用阿瑞匹坦的患者被随机分为两组：延长使用阿瑞匹坦（PA；6 天阿瑞匹坦）和标准使用阿瑞匹坦（SA；3 天阿瑞匹坦）；拒绝使用阿瑞匹坦的患者被纳入对照组（C 组）。主要终点包括安全性和无化疗引起的恶心和呕吐天数。三组不良事件无统计学差异。PA 组（18.28 ± 3.35）无化疗引起的恶心和呕吐天数明显长于 SA 组和 C 组。此外，根据功能性生活指数-呕吐问卷，PA 组的生活功能评分更好。在这项研究中，6 天阿瑞匹坦方案在控制 3 天顺铂方案引起的化疗引起的恶心和呕吐方面比标准的 3 天阿瑞匹坦方案更安全、更有效。
